AestheticsFeatured Articles

Increased Trend of Cosmetic Procedures in Patients With Psoriasis Who Attain 75% or Greater Improvement

By August 25, 2020No Comments

Featured Article

Featured Article

A survey was conducted at a single dermatology center to determine if there was an increased trend in cosmetic procedures in patients with moderate to severe psoriasis who attained 75% or greater reduction of the body surface area (BSA) with biologic agents and oral systemic therapies, and if this was related to an improvement in quality of life following psoriasis clearance.

Read more

A survey was conducted at a single dermatology center to determine if there was an increased trend in cosmetic procedures in patients with moderate to severe psoriasis who attained 75% or greater reduction of the body surface area (BSA) with biologic agents and oral systemic therapies, and if this was related to an improvement in quality of life following psoriasis clearance.

Michelle E. Walters MD, Delphine J. Lee MD PhD, Paul S. Yamauchi MD PhD

Psoriasis is a chronic skin condition with a negative impact on patient quality of life. The National Psoriasis Foundation states that an acceptable response to psoriasis treatment is at least a 75% reduction in body surface area (BSA) at 3 months after initiation of treatment.

This reduction in BSA has been associated with improvement in quality of life, with clearance rates of clear to almost clear leading to an even greater improvement in quality of life.2,3 To date, there have been no studies examining the relationship between improvement in quality of life following a reduction in BSA, and the increased utilization of cosmetic procedures. Here, we examine the relationship between quality of life and the use of various cosmetic procedures in patients treated for psoriasis with systemic and biologic therapies who achieved at least 75% reduction in BSA.

This was a retrospective study assessing quality of life and the use of cosmetic procedures in psoriasis patients after attaining a75% or greater reduction of the body surface area with biologic agents only, systemic agents only, or a combination of both. This study was conducted according to the ethical guidelines of the 1975 Declaration of Helsinki. All patients provided informed consent.

Read Full Article Now
Article Cited in this Post

You May Also Like

Journal of Drugs in Dermatology JDD featuring Dr. Jacob Beer in JDD Re:View, a discussion of JDD articles and specific topics. This article highlights navigating the New Dermatology Landscape: Billing, Virtual Care, and the Rise of DermTok.

JDD Re:View With Dr. Beer

| Featured Articles, JDD Re:View, Latest News | No Comments
Navigating the New Dermatology Landscape: Billing, Virtual Care, and the Rise of DermTok In the past several years, managing and running a dermatology practice has changed drastically. These changes have…
Journal of Drugs in Dermatology JDD Article about Scar Wars: A Review of Topical Scar Therapies

Scar Wars: A Review of Topical Scar Therapies

| Featured Articles, Latest News, Medical Derm | No Comments
Review places silicone and occlusion as first‑line topical therapy, with retinoids, pressure, corticosteroids and cannabinoids as situational tools amid limited high‑quality evidence Scarring reflects replacement of normal dermis by fibroblast-driven,…
Journal of Drugs in Dermatology JDD Article about Maximizing a Focused Vitiligo Patient Visit: A Practical Approach

Maximizing a Focused Vitiligo Patient Visit: A Practical Approach

| Case Reports, Featured Articles, Latest News, Medical Derm | No Comments
Efficient history, targeted exam, selective labs and clear shared‑decision plans let dermatologists deliver meaningful vitiligo care in time‑pressed visits In routine practice, non‑segmental vitiligo (NSV) visits can be both brief…

Leave a Reply